HEXABRIX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hexabrix, and what generic alternatives are available?
Hexabrix is a drug marketed by Guerbet and is included in one NDA.
The generic ingredient in HEXABRIX is ioxaglate meglumine; ioxaglate sodium. Additional details are available on the ioxaglate meglumine; ioxaglate sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEXABRIX?
- What are the global sales for HEXABRIX?
- What is Average Wholesale Price for HEXABRIX?
Summary for HEXABRIX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 21 |
| Clinical Trials: | 2 |
| Patent Applications: | 100 |
| DailyMed Link: | HEXABRIX at DailyMed |
Recent Clinical Trials for HEXABRIX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guerbet | Phase 4 |
| NYU Langone Health | Phase 4 |
| New York University School of Medicine | Phase 4 |
US Patents and Regulatory Information for HEXABRIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HEXABRIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Guerbet | HEXABRIX | ioxaglate meglumine; ioxaglate sodium | INJECTABLE;INJECTION | 018905-002 | Jul 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HEXABRIX
See the table below for patents covering HEXABRIX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 7503131 | ⤷ Sign Up | |
| U.S.S.R. | 652884 | METHOD OF OBTAINING POLYIODINED DERIVATIVES OF BENZOL | ⤷ Sign Up |
| Brazil | 7503444 | ⤷ Sign Up | |
| Hungary | 174153 | SPOSOB POLUCHENIJA PROIZVODNYKH 2,4,6-TRIIODO-BIS-2,4,6-TRIIODO-3,5-BIS-SKOBKA-KARBAMOIL-SKOBKA ZAKRYTA-FENIL-KARBAMOIL-METIL-AMINO-ACETAMIDO-5-BENZOJJNOJJ KISLOTY (PROCESS FOR PRODUCING 2,4,6-TRIIODO-BIS-2,4,6-TRIIODO-3,5-BIS-BRACKET-CARBAMOYL-BRACKET CLOSED-PHENYL-CARBAMOYL-METHYL-AMINO-ACETAMIDO-5-BENZOIC ACID DERIVATIVES) | ⤷ Sign Up |
| Norway | 793035 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
